Your Health, We Care
December 20, 2024: The U.S. Food and Drug Administration (FDA) approved Pfizer’s Encorafenib combination regimen as the first-line treatment for BRAF V600E-mutant metastatic colorectal cancer.
October 11, 2023: The U.S. Food and Drug Administration (FDA) approved Encorafenib in combination with Binimetinib for the treatment of BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
April 8, 2020: The U.S. Food and Drug Administration (FDA) approved Encorafenib in combination with Cetuximab for the treatment of BRAF V600E-mutant metastatic colorectal cancer (CRC) in patients who have received prior therapy.
June 27, 2018: Array BioPharma announced the U.S. Food and Drug Administration (FDA) approval of Encorafenib in combination with Binimetinib for the treatment of unresectable or metastatic melanoma with BRAF mutations.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
